Soaring Demand Set to Propel Drugs for Immunotherapy Market to $445.12 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Drugs for Immunotherapy Market Through 2025?
Recent years have seen swift growth in the immunotherapy drugs market size. An upsurge from $255.14 billion in 2024 to $281.43 billion in 2025, outlining a compound annual growth rate (CAGR) of 10.3%, is expected. The substantial growth during the historic period can be traced back to the increased occurrences of cancer, unfulfilled medical necessities, awareness about cancer immunotherapy, broader acceptance of therapeutic approaches in immunotherapy, and heightened investment from pharmaceutical industry giants.

What's the Projected Size of the Global Drugs for Immunotherapy Market by 2029?
The market size for immunotherapy drugs is predicted to undergo swift expansion in the upcoming years, reaching a value of $445.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The forecasted period's growth is linked to combination therapies, personalized medication, worldwide expansion, therapies driven by biomarkers, and the rise in clinical trials. Key trends for this anticipated period encompass advancements in immunology and car-t cell therapies, targeted immunotherapy, combination immunotherapies, and neoantigen vaccines.

View the full report here:
https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Top Growth Drivers in the Drugs for Immunotherapy Industry: What's Accelerating the Market?
Rising global cancer rates are fueling the growth of the immunotherapy drugs market. The leading contributors to the onset of most cancers are known to be obesity, smoking, alcohol consumption, and poor diet. For example, according to the UK's largest healthcare charity, Macmillan Cancer Support, the number of cancer patients is forecasted to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Breast, lung, colon, , and prostate cancers are the most common types. Factors such as tobacco use, high body mass index, alcohol intake, low fruit and vegetable consumption, and lack of physical activity contribute to roughly a third of cancer-related deaths. These escalating cancer rates are anticipated to enhance the need for immunotherapy drugs, thus propelling the growth of their market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp

What Trends Will Shape the Drugs for Immunotherapy Market Through 2029 and Beyond?
Key players in the immunotherapy drugs market are prioritizing the development of innovative products like Keytruda (pembrolizumab) to deliver high-quality services to their consumers. Keytruda (pembrolizumab) is an immunotherapy form which employs a targeted drug known as an immune checkpoint inhibitor, designed for adult patients. For example, in January 2023, the American pharmaceutical corporation, Merck & Co., Inc., introduced Keytruda (pembrolizumab). This product received approval from the Food and Drug Administration, a federal agency based in the United States. Keytruda (pembrolizumab) immunotherapy aids in treating diverse cancer types by collaborating with the immune system to combat cancerous cells. It is sanctioned as an auxiliary treatment for non-small cell lung cancer (NSCLC). This breakthrough in cancer therapeutics is suspected to carry positive implications for the healthcare sector.

What Are the Main Segments in the Drugs for Immunotherapy Market?
The drugs for immunotherapy market covered in this report is segmented -

1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma
3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)
4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines
5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2559&type=smp

Which Top Companies are Driving Growth in the Drugs for Immunotherapy Market?
Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

Which Regions Will Dominate the Drugs for Immunotherapy Market Through 2029?
The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2559

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.